Base Editing News Today

Genome Engineering Editing is a modern molecular biology technology that involves targeted modifications to the genome of an organism to change the sequence of a target gene or regulate its expression. This technology is largely based on genome editing tools such as CRISPR-Cas9, which allows scientists to precisely add, delete or replace an organism-s genes. According to the new market research report “Global Genome Engineering Editing Market Report 2023-2029”, published by QYResearc

Plus: This year’s 30 Under 30 Europe list for science and healthcare

Plus: The consortium building the digital tools that hospitals actually need.

Plus: eGenesis, the startup behind the first pig-human kidney transplant, is targeting hearts and livers next.

Dublin, Feb. 13, 2024 (GLOBE NEWSWIRE) -- The

/PRNewswire/ -- The base editing market value is anticipated to grow by USD 307.66 million, progressing at a CAGR of 15.1% and a YOY growth rate of 13.51%...

Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates (NHPs) and miceFunctional effect demonstrated in mice in vivo via modulation of ANGPLT3 protein properties leading to favorable increase in LPL enzymatic activity and meaningful impact of biomarkersAdditional data to be presented throughout 2024, including in vitro and in vivo data for pipeline programs AX-0810 for Cholestatic diseases targeting NTCP and AX-1412 for Ca

One-time treatment offers hope that people with one of the world’s most common inherited blood disorders could no longer need transfusions.

/PRNewswire/ -- On January 8, 2024, Shanghai,China, CorrectSequence Therapeutics Co., Ltd. (Correctseq), using innovative transformer Base Editing (tBE)...

CorrectSequence Therapeutics' CS-101 Successfully Cures One Patient of Transfusion-Dependent β-Thalassemia